Bemarituzumab FIGHTs Gastric/GEJ Cancers, Improving Survival
Adding bemarituzumab to chemotherapy as first-line treatment for advanced gastric and gastroesophageal junction (GEJ) cancers improved survival over chemotherapy alone in the phase 2 FIGHT trial. Medscape Medical News